Australian antiviral drug development company Island Pharmaceuticals has completed subject dosing for the phase 2b ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

Detailed price information for Nervgen Pharma Corp (NGENF) from The Globe and Mail including charting and trades.

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and ...

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key MetricsFindings Highlight ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

Recently, the company received IRB approval for an amendment focused on the subacute cohort of its Phase 1b/2a clinical trial. Key changes to the protocol were implemented to facilitate enrollment ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

Phase 2a trials demonstrated Sepranolone's potential to significantly reduce Tourette symptoms and improve quality of life while maintaining a robust safety profile, making it a promising first ...

According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...